Syndax Pharmaceuticals (SNDX) Common Equity: 2015-2025
Historic Common Equity for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $115.4 million.
- Syndax Pharmaceuticals' Common Equity fell 68.50% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 68.50%. This contributed to the annual value of $288.1 million for FY2024, which is 48.01% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Common Equity stood at $115.4 million for Q3 2025, which was down 26.68% from $157.4 million recorded in Q2 2025.
- Syndax Pharmaceuticals' Common Equity's 5-year high stood at $554.2 million during Q4 2023, with a 5-year trough of $115.4 million in Q3 2025.
- In the last 3 years, Syndax Pharmaceuticals' Common Equity had a median value of $366.4 million in 2024 and averaged $347.1 million.
- Per our database at Business Quant, Syndax Pharmaceuticals' Common Equity spiked by 326.48% in 2021 and then crashed by 68.50% in 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Common Equity (Quarterly) stood at $408.4 million in 2021, then climbed by 14.47% to $467.4 million in 2022, then climbed by 18.56% to $554.2 million in 2023, then crashed by 48.01% to $288.1 million in 2024, then tumbled by 68.50% to $115.4 million in 2025.
- Its Common Equity was $115.4 million in Q3 2025, compared to $157.4 million in Q2 2025 and $215.1 million in Q1 2025.